Newsroom

 

October 19, 2018

TerSera Therapeutics LLC announces U.S. FDA Approval of Qmiiz ODT (meloxicam orally disintegrating tablets). U.S. commercial launch planned for early 2019.




February 20, 2017

AstraZeneca announced today that it has entered into an agreement with TerSera Therapeutics LLC (“TerSera”) for the commercial rights to Zoladex (goserelin acetate implant) in the US and Canada. This transaction is expected to close during Q1 of 2017.